M. de Locht

Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies.

Johan R. Boelaert, M. de Locht, J. Van Cutsem et al. · Journal of Clinical Investigation · 1993 · 341 citations · Full text

Deferoxamine Therapy, Antifungal Agent, Fungal Uptake +14

Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect

Johan R. Boelaert, J. Van Cutsem, M. de Locht et al. · Kidney International · 1994 · 167 citations · Full text

Hydroxypyridinone Chelators, Biochemistry, Medicine +6

Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of rhizopus microsporus

M. de Locht, Johan R. Boelaert, Yves‐Jacques Schneider · Biochemical Pharmacology · 1994 · 121 citations

Nutrient Bioavailability, Rhizopus Microsporus, Microbial Ecology +6

Side-effects of desferrioxamine in dialysis patients

Johan R. Boelaert, M. de Locht · Nephrology Dialysis Transplantation · 1993 · 69 citations

Dialysis, Renal Pathology, Renal Inflammation +18

Desferrioxamine

Johan R. Boelaert, M. de Locht, J. Van Cutsem · Reviews in Medical Microbiology · 1993 · 14 citations

Desferrioxamine Stimulates Growth, Medical Microbiology, Health Sciences +9